Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Archived opportunity record

Cancer Adoptive Cellular Therapy Network is closed (last close March 6, 2024). The parent program page for CFDA 93.395 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Wide-open applicant board · 15 Grants.gov doors

Cancer Adoptive Cellular Therapy Network prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).

Code 00

State governments

Code 01

County governments

Code 02

City or township governments

Code 04

Special district governments

Code 05

Independent school districts

Code 06

Public / state-controlled institutions of higher education

Code 07

Federally recognized tribal governments

Code 08

Public / Indian housing authorities

Code 11

Native American tribal organizations (other than Federally recognized tribal governments)

Code 12

Nonprofits with 501(c)(3) status (other than IHEs)

Code 13

Nonprofits without 501(c)(3) status (other than IHEs)

Code 20

Private institutions of higher education

Code 22

For-profit organizations other than small businesses

Code 23

Small businesses

Code 25

Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.